NEW YORK, March 23, 2021 /PRNewswire/ — As COVID-19 vaccinations continue to roll out across the country, many Americans are anticipating their long-awaited turn to get the vaccine. After a year of living in a pandemic, the public’s desire for a COVID-19 shot is producing conflicting feelings.
ValuePenguin surveyed more than 1,000 consumers and found some are frustrated that high-profile Americans and celebrities have been able to skirt the system to get a vaccine before others, while other Americans admit they would pay to be moved up in the vaccination line.
Key findings:
View full report: People Willing to Pay to Move Up in Vaccination Line
About ValuePenguin.com: ValuePenguin.com, part of LendingTree (NASDAQ: TREE), is a personal finance website that conducts in-depth research and provides objective analysis to help guide consumers to the best financial decisions. ValuePenguin focuses on value, assessing whether the return of a particular decision is worth the cost or risk of that option, and how this stacks up with the other possible choices they may have. For more information, please visit www.valuepenguin.com, like our Facebook page, or follow us on Twitter @ValuePenguin.
Media Contact:
Nadia Gonzalez (Mrs.)
Nadia@LendingTreeNews.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/57-of-americans-admit-they-would-pay-to-move-up-in-the-covid-19-vaccination-line-according-to-a-valuepenguincom-survey-301253516.html
SOURCE ValuePenguin.com
Vancouver, British Columbia--(Newsfile Corp. - May 2, 2025) - Beyond Medical Technologies Inc. (CSE: DOCT)…
With fresh funding round, the health tech pioneer continues to work toward managing the world's…
STOCKHOLM, May 2, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces the launch of RayStation®*…
Dublin, Ireland--(Newsfile Corp. - May 2, 2025) - Cosmo is excited to announce that Endovision…
Poison Help (1-800-222-1222/ PoisonHelp.org) provides 24/7 free, expert advice from one of 53 nationally accredited,…
Siemens is the first of many partners to non-exclusively license SpeechDx's speech and clinical dataset…